Skip to main content

Branded

  • FDA launches advisory committee membership nomination portal

    SILVER SPRING, Md. — The Food and Drug Administration on Wednesday launched the advisory committee membership nomination portal, an online, interactive system that allows interested individuals to submit nominations for membership to any of the agency’s 33 advisory committees.  

  • Avion Pharmaceuticals launches prescription supplements Prenate Enhance and Prenate Restore

    ATLANTA — Avion Pharmaceuticals on Tuesday announced the launch of two advanced vitamin formulations as the newest additions to the Prenate Vitamin Family — Prenate Enhance and Prenate Restore.

    The new prescription supplements have been designed to support important nutritional supplementation for women during their prenatal and postpartum period, as well as provide the optimal level of vitamins and minerals recommended.

  • Study: Pharmacist intervention improves shingles vaccine rate

    COLUMBUS, Ohio - A new study from researchers at Ohio State University is reporting that older patients who receive written information on shingles were almost three times more likely to get vaccinated than those that didn’t receive a similar communication. The study is also one of the first to show that using a patient’s electronic medical record coupled with pharmacist intervention markedly improves preventative care of shingles over the current standard.

  • Takeda and Lundbeck announce Brintellix for treatment of MDD

    DEERFIELD, Ill. — Takeda Pharmaceuticals U.S.A. and Lundbeck on Tuesday announced the availability of Brintellix (vortioxetine) — a once-daily oral antidepressant for treatment of major depressive disorder in adults — in pharmacies across the United States.

    “MDD continues to be a challenging condition to manage, and we are proud to make Brintellix available as a new treatment option for people struggling with major depression,” said Douglas Cole, president of Takeda Pharmaceuticals U.S.A.

  • IMS Institute report: Half of all pharmaceutical manufacturers actively using social media

    PARSIPPANY, N.J. — With the role of social media rapidly expanding, nearly half of pharmaceutical manufacturers are now actively using this channel to engage with patients on healthcare-related topics, according to a new report released Tuesday by the IMS Institute for Healthcare Informatics. 

  • Greenstone launches authorized generic of Pfizer's Rapamune

    PEAPACK, N.J. — Greenstone, a U.S.-based generic pharmaceutical subsidiary of Pfizer, on Tuesday announced the introduction of Sirolimus to its generic pharmaceutical product line. The product is offered in dosage strengths of 0.5mg x 100. 

    Greenstone’s Sirolimus product is the authorized generic of, and equivalent to, Pfizer's Rapamune (sirolimus). 

  • Teva Pharmaceutical acquires NuPathe and migraine patch Zecuity

    JERUSALEM — Teva Pharmaceutical on Tuesday announced that it has entered into a definitive agreement under which Teva will acquire NuPathe for $3.65 per share in cash, or approximately $144 million. In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment, Zecuity, are achieved over time.

  • Novo Nordisk launches new insulin device

    NEW YORK — Novo Nordisk has launched a new insulin pen designed for children with diabetes.

    The new NovoPen Echo is the first and only prefilled pen device in the United States that allows for half-unit dosing in combination with a memory function, the company said.

X
This ad will auto-close in 10 seconds